Clinical Trials · NCT05755360
DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 291
- Start date
- Feb 2023
- Locations
- 25 sites, Italy
- Primary endpoint
- Absolute change in glycated haemoglobin (HbA1c) (percentage [%]-point)